Table 1.
Participant Characteristics
| Demographics | |
|---|---|
| Age, y | 68.5 ± 14.9 |
| Sex | |
| Male | 13 (57%) |
| Female | 10 (43%) |
| Race | |
| Asian | 4 (17%) |
| Black | 0 (0%) |
| White | 16 (70%) |
| Other | 2 (9%) |
| Unknown | 1 (4%) |
| Latinx status | |
| Latinx | 8 (35%) |
| Not Latinx | 14 (61%) |
| Unknown | 1 (4%) |
| BMI, kg/m2 | 24.7 ± 5.6 |
| Comorbidity | |
| Chronic cardiac disease (other than hypertension) | 7 (30%) |
| Chronic pulmonary disease (chronic obstructive pulmonary disease, asthma) | 3 (13%) |
| Hypertension | 13 (57%) |
| Chronic kidney disease | 7 (30%) |
| Chronic liver disease | 0 (0%) |
| Cancer | 2 (9%) |
| Human immunodeficiency virus | 0 (0%) |
| Diabetes | 7 (30%) |
| Organ transplant | 5 (22%) |
| Any other form of immunosuppression | 6 (26%) |
| Obesity (BMI >30 kg/m2) | 3 (13%) |
| Chronic oxygen requirement | 0 (0%) |
| None | 3 (13%) |
| Baseline characteristics/laboratory results at time of first leronlimab dose | |
| Days of symptoms | 9.7 ± 6.5 |
| Vasopressor support | 5 (22%) |
| Low-flow supplemental oxygen | 12 (52%) |
| High-flow supplemental oxygen | 3 (13%) |
| Mechanical ventilation | 7 (30%) |
| White blood cell count, 103 cells/µL | 6.74 ± 3.10 |
| Absolute neutrophil count, 103 cells/µL | 4.88 ± 2.67 |
| Absolute lymphocyte count, 103 cells/µL | 1.05 ± .59 |
| Neutrophil-to-lymphocyte ratio | 6.34 ± 5.60 |
| Lactate dehydrogenase, U/L | 366 ± 142 |
| Ferritin, µg/L | 2235 ± 2332 |
| D-Dimer, mg/L | 3018 ± 2850 |
| C-reactive protein, mg/L | 9.2 ± 7.9 |
| Other coronavirus disease 2019 therapies | |
| Hydroxychloroquine (open label) | 7 (30%) |
| Tocilizumab (open label) | 2 (9%) |
| Sarilumab clinical trial (placebo-controlled) | 1 (4%) |
| Selinexor clinical trial (placebo-controlled) | 1 (4%) |
| High-dose steroids | 3 (13%) |
| Remdesivira | 1 (4%) |
| Convalescent plasma (open label) | 10 (43%) |
| Outcomes (day 30) | |
| Recovered, no supplemental oxygen required | 16 (70%) |
| Recovered, low-flow oxygen required | 1 (4%) |
| Still hospitalized | 2 (9%) |
| Died | 4 (17%) |
Abbreviation: BMI, body mass index.
aTwo persons were enrolled in a randomized, controlled trial of remdesivir; unblinding revealed that 1 received remdesivir and 1 received placebo.